FY2025 EPS Estimate for Sanara MedTech Increased by Analyst

Sanara MedTech Inc. (NASDAQ:SMTI - Free Report) - Research analysts at Cantor Fitzgerald lifted their FY2025 EPS estimates for shares of Sanara MedTech in a note issued to investors on Thursday, May 15th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will earn ($1.78) per share for the year, up from their previous forecast of ($2.43). Cantor Fitzgerald has a "Overweight" rating and a $46.00 price objective on the stock. The consensus estimate for Sanara MedTech's current full-year earnings is ($1.10) per share.

Separately, HC Wainwright increased their price target on shares of Sanara MedTech from $51.00 to $53.00 and gave the company a "buy" rating in a report on Thursday.

Sanara MedTech Stock Up 2.0%

Shares of NASDAQ:SMTI opened at $31.50 on Monday. The company has a current ratio of 2.23, a quick ratio of 2.02 and a debt-to-equity ratio of 0.76. The stock has a fifty day simple moving average of $31.06 and a two-hundred day simple moving average of $33.45. Sanara MedTech has a 12-month low of $25.86 and a 12-month high of $39.08. The stock has a market capitalization of $279.97 million, a price-to-earnings ratio of -31.82 and a beta of 1.38.

Sanara MedTech (NASDAQ:SMTI - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.10). The company had revenue of $23.43 million for the quarter, compared to analysts' expectations of $23.48 million. Sanara MedTech had a negative net margin of 10.71% and a negative return on equity of 19.86%.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of SMTI. Marshall Wace LLP bought a new stake in shares of Sanara MedTech during the fourth quarter valued at approximately $1,005,000. Fifth Third Bancorp purchased a new position in Sanara MedTech during the fourth quarter valued at $898,000. Renaissance Technologies LLC increased its holdings in Sanara MedTech by 152.9% in the 4th quarter. Renaissance Technologies LLC now owns 35,400 shares of the company's stock valued at $1,175,000 after acquiring an additional 21,400 shares during the last quarter. Nuveen LLC bought a new position in shares of Sanara MedTech during the 1st quarter valued at about $326,000. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Sanara MedTech by 234.5% during the 4th quarter. JPMorgan Chase & Co. now owns 13,574 shares of the company's stock valued at $451,000 after purchasing an additional 9,516 shares during the last quarter. Institutional investors own 8.10% of the company's stock.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.